BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35027731)

  • 21. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
    Jokinen EM; Gopinath K; Kurkinen ST; Pentikainen OT
    IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1281-1289. PubMed ID: 33914685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
    Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
    Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
    Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
    J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
    Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
    Front Immunol; 2022; 13():811430. PubMed ID: 35250984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection.
    Sun H; Su X; Huang L; Mu D; Qu Y
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33573324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
    Lu J; Hou Y; Ge S; Wang X; Wang J; Hu T; Lv Y; He H; Wang C
    Life Sci; 2021 Feb; 266():118889. PubMed ID: 33310043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study.
    Li Q; Lu H; Ruan Y; Geng Y; Zhao Z; Liu Y; Feng L; Guo W
    Antivir Ther; 2024 Jun; 29(3):13596535241259952. PubMed ID: 38873947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-chain polyphosphates impair SARS-CoV-2 infection and replication.
    Ferrucci V; Kong DY; Asadzadeh F; Marrone L; Boccia A; Siciliano R; Criscuolo G; Anastasio C; Quarantelli F; Comegna M; Pisano I; Passariello M; Iacobucci I; Monica RD; Izzo B; Cerino P; Fusco G; Viscardi M; Brandi S; Pierri BM; Borriello G; Tiberio C; Atripaldi L; Bianchi M; Paolella G; Capoluongo E; Castaldo G; Chiariotti L; Monti M; De Lorenzo C; Yun KS; Pascarella S; Cheong JH; Kim HY; Zollo M
    Sci Signal; 2021 Jul; 14(690):. PubMed ID: 34230209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
    Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
    J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
    Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
    Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 receptor networks in diabetic and COVID-19-associated kidney disease.
    Menon R; Otto EA; Sealfon R; Nair V; Wong AK; Theesfeld CL; Chen X; Wang Y; Boppana AS; Luo J; Yang Y; Kasson PM; Schaub JA; Berthier CC; Eddy S; Lienczewski CC; Godfrey B; Dagenais SL; Sohaney R; Hartman J; Fermin D; Subramanian L; Looker HC; Harder JL; Mariani LH; Hodgin JB; Sexton JZ; Wobus CE; Naik AS; Nelson RG; Troyanskaya OG; Kretzler M
    Kidney Int; 2020 Dec; 98(6):1502-1518. PubMed ID: 33038424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
    Leach A; Ilca FT; Akbar Z; Ferrari M; Bentley EM; Mattiuzzo G; Onuoha S; Miller A; Ali H; Rabbitts TH
    Antiviral Res; 2021 Oct; 194():105147. PubMed ID: 34375715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes.
    Guney C; Akar F
    J Pharm Pharm Sci; 2021; 24():84-93. PubMed ID: 33626315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of the SARS-CoV-2 receptor ACE2 is induced by cigarette smoke in bronchial and alveolar epithelia.
    Liu A; Zhang X; Li R; Zheng M; Yang S; Dai L; Wu A; Hu C; Huang Y; Xie M; Chen Q
    J Pathol; 2021 Jan; 253(1):17-30. PubMed ID: 32991738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-IT-TOF-MS approach.
    Lv Y; Wang S; Liang P; Wang Y; Zhang X; Jia Q; Fu J; Han S; He L
    Anal Bioanal Chem; 2021 May; 413(11):2995-3004. PubMed ID: 33608752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening.
    Ebisudani T; Sugimoto S; Haga K; Mitsuishi A; Takai-Todaka R; Fujii M; Toshimitsu K; Hamamoto J; Sugihara K; Hishida T; Asamura H; Fukunaga K; Yasuda H; Katayama K; Sato T
    Cell Rep; 2021 Jun; 35(10):109218. PubMed ID: 34038715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.
    Brevini T; Maes M; Webb GJ; John BV; Fuchs CD; Buescher G; Wang L; Griffiths C; Brown ML; Scott WE; Pereyra-Gerber P; Gelson WTH; Brown S; Dillon S; Muraro D; Sharp J; Neary M; Box H; Tatham L; Stewart J; Curley P; Pertinez H; Forrest S; Mlcochova P; Varankar SS; Darvish-Damavandi M; Mulcahy VL; Kuc RE; Williams TL; Heslop JA; Rossetti D; Tysoe OC; Galanakis V; Vila-Gonzalez M; Crozier TWM; Bargehr J; Sinha S; Upponi SS; Fear C; Swift L; Saeb-Parsy K; Davies SE; Wester A; Hagström H; Melum E; Clements D; Humphreys P; Herriott J; Kijak E; Cox H; Bramwell C; Valentijn A; Illingworth CJR; ; Dahman B; Bastaich DR; Ferreira RD; Marjot T; Barnes E; Moon AM; Barritt AS; Gupta RK; Baker S; Davenport AP; Corbett G; Gorgoulis VG; Buczacki SJA; Lee JH; Matheson NJ; Trauner M; Fisher AJ; Gibbs P; Butler AJ; Watson CJE; Mells GF; Dougan G; Owen A; Lohse AW; Vallier L; Sampaziotis F
    Nature; 2023 Mar; 615(7950):134-142. PubMed ID: 36470304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity.
    Saiz ML; DeDiego ML; López-García D; Corte-Iglesias V; Baragaño Raneros A; Astola I; Asensi V; López-Larrea C; Suarez-Alvarez B
    Clin Epigenetics; 2021 Oct; 13(1):187. PubMed ID: 34635175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
    Shukla SP; Cho KB; Rustagi V; Gao X; Fu X; Zhang SX; Guo B; Udugamasooriya DG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.